

VALUE-BASED PROGRAMS THROUGH SAFEGUARDRX® FOR CIGNA

Helping drive down costs for complex, costly conditions

Through our strengthened contracting agreements with pharmaceutical manufacturers, we hold pharma accountable for the value and efficiency of select high-cost therapies. We also leverage our clinical coaching to drive improved outcomes.



Greater value and reduced financial risk for ASO Clients

With our value-based programs through SafeGuardRx for Cigna, we limit our ASO clients' financial exposure and drive down costs for certain complex, costly conditions, including:¹

- **Diabetes, Inflammatory, Oncology, Weight Management, Multiple Sclerosis, and Preventive Migraine and Epilepsy:** Cigna credits clients for new-to-therapy customers who discontinue select preferred drugs within the first 90 days of therapy.
- **Inflammatory, Diabetes, and Hepatitis C conditions:** For select preferred drugs and devices (Continuous Glucose Monitors for Diabetes), Cigna will offer additional discounts to clients for new-to-therapy customers.
- **Acute Migraine** – Cigna credits clients when customers use a certain amount of preferred acute migraine medications. These credits are considered “use threshold credits,” meaning their value will increase when customers exceed five medication fills of any eligible drug in this class, per customer per year.
- **Cardiovascular and Rare Conditions:** For select preferred drugs within the rare conditions category and for Repatha®, a cardiovascular drug, Cigna offers a cost cap – a credit to clients for costs above a certain threshold.



Adherence coaching for conditions

Cigna is strengthening our adherence coaching program for customers with diabetes, pulmonary, cardiovascular, preventive migraine, epilepsy and obesity conditions.

- **Proactive customer outreach:** Targeted customers are encouraged to be connected with a trained clinician to talk through any drug adherence related questions they may have. Customers can engage with a Cigna clinical pharmacist as often as needed.
- In addition to extensive **outreach to customers, predictive analytics** will identify and proactively outreach to prescribers with at-risk patients for whom a Continuous Glucose Monitor would be cost effective and benefit their condition.
- **Proven success to help lower A1C levels:** For customers with diabetes who respond to our outreach, we guide them to speak with a Cigna coach specializing in diabetes. Of those callers with an A1C level of 8 or above, **63% were able to lower it to a goal of less than 8.**^{2,3}
- **Provider care alerts:** For providers treating customers with triptans for migraines we will send alerts when overuse is noted.



Engaged customers

WITH INTEGRATED BENEFITS

LIVING WITH

diabetes

SAVE APPROXIMATELY

\$2,777

PER MEMBER PER YEAR
AND HAVE

13%

HIGHER ENGAGEMENT.⁴



Drug classes eligible for this program⁵

| THERAPEUTIC CLASS | DRUG NAME |
|--------------------------------|---|
| Cardiovascular | Eliquis® Repatha® Xarelto® |
| Diabetes | Basaglar®* Bydureon®, Bydureon BCise® Byetta® Farxiga® Glyxambi® Humalog® Humulin® Insulin Glargine** Insulin Lispro* Janumet®/Janumet XR*** Januvia®** Jardiance® Jentadueto®/Jentadueto XR®* Levemir® Lyumjev™ Novolin® Ozempic® Rybelsus® Segluromet*** Semglee*** Steglatro*** Steglujan*** Symlin Pen® Synjardy®/Synjardy XR® Toujeo*** Tadjenta®* Tresiba® Trijardy XR® Trulicity® Victoza®* Xigduo XR® |
| Hepatitis C | Epclusa® Harvoni® |
| Inflammatory/Atopic Conditions | Actemra® Cimzia® Enbrel® Fasenra® Humira®** Kevzara® Otezla*** Rinvoq*** Simponi® Skyrizi*** Stelara® |

| THERAPEUTIC CLASS | DRUG NAME |
|--|--|
| Inflammatory/Atopic Conditions (cont) | Taltz® Tremfya® Xeljanz®/Xeljanz XR*** |
| Multiple Sclerosis | Avonex®** Betaseron® Gilenya®** Kesimpta*** Mavenclad*** Mayzent*** Plegridy*** Ponvory*** Rebif*** Vumerity*** |
| Neurological | Epilepsy Briviact® Migraine Aimovig® Ajovy® Emgality*** Nurtec ODT® Reyvow*** Ubrelvy® |
| Oncology | Verzenio® |
| Pulmonary | Advair HFA*** Anoro™ Ellipta® Arnuity™ Ellipta*** Bevespi Aerosphere*** Breo® Ellipta*** Breztri Aerosphere® Flovent® Incruse® Ellipta*** Pulmicort® Qvar RediHaler® Spiriva® Stiolto® Respimat® Symbicort® Trelegy™ Ellipta® |
| Rare Conditions | Strensiq® (hypophosphatasia) Tobi® Podhaler*** (cystic fibrosis) |
| Weight Management | Saxenda® Wegovy® |

* Formulary exception for National Preferred Formulary.

** Formulary exception for Total Savings Formulary.

Automatic enrollment for our clients

All Cigna commercial self-funded clients are automatically enrolled in SafeGuardRx for Cigna.

- ✓ **No action for clients**
- ✓ **No benefit restrictions**
- ✓ **No disruption to customers**
- ✓ **No additional fees**
- ✓ **Annual credit payout & reporting**



Contact us

This is just another example of how we continue to leverage Express Scripts® capabilities to enhance Cigna's administration of integrated benefits. To learn more about how SafeGuardRx for Cigna can help you and your employees, please contact your Cigna sales representative.



1. In addition to retaining other manufacturer revenue that Cigna directly or indirectly earns in connection with SafeGuardRx, Cigna will also not pay discontinuation credits or cost cap value to those clients for which Cigna bears the financial risk for benefit payments as between Cigna and the client (i.e., insured and ASO clients whose claims payments exceed Cigna-issued stop-loss limits).
2. Cigna National Book of Business analysis of SafeGuardRx for Cigna medication adherence outreach. Full year 2020. Results may vary.
3. All About Your A1C. Centers for Disease Control and Prevention. www.cdc.gov. Accessed January 4, 2021.
4. Cigna Book of Business study of medical customers with integrated medical, pharmacy and total behavioral health vs. those with Cigna medical and carved-out pharmacy. Individual results will vary; not guaranteed. Average annual per member per year (PMPY) and per patient per year (PMPY). Full year 2020. Results may vary.
5. List of eligible drugs is as of October 2022 and subject to change. Additional value may be realized by Cigna as additional drugs or drug categories are added to programs. The list of drug categories or select drugs for which manufacturer revenue is earned by Cigna might vary over time and are generally specific to preferred drugs within each therapeutic class.

This document provides program highlights only. It is not a contract. Coverage for eligible drugs will be administered according to the applicable plan documents, including plan exclusions and limitations.

Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, contact a Cigna representative.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company (CHLIC) and Express Scripts, Inc. or their affiliates. The Cigna name, logo, and "Together, all the way." are trademarks of Cigna Intellectual Property, Inc. "SafeGuardRx" and "Express Scripts" are trademarks of Express Scripts Strategic Development, Inc. All pictures are used for illustrative purposes only.